RxDoctor Payments DataLook up a doctor →

Zaher Hakim, MD

Interventional Cardiology · Detroit, MINPI 1306191853

Payments from drug & device makers

$91,695in general payments, 2019–2025

Across 428 payments — averaging $214.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$66K
  • Cardiovascular Systems Inc.$12K
  • Penumbra, Inc.$2K
  • Boston Scientific$2K
  • Abbott$2K
  • Stryker$1K
  • plus $7K from 31 others

What the payments were for

  • Consulting fees$3,8004%
  • Speaking & faculty fees$65,25571%
  • Travel & lodging$6,7537%
  • Food & beverage$15,57817%
  • Education$3090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,695 in reported general payments places this provider in the 75th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$212,990
Medicare patients
520
Services billed
2,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin81$78,962
EntrestoSacubitril/Valsartan46$53,323
OzempicSemaglutide39$48,631
XareltoRivaroxaban44$36,812
EliquisApixaban37$34,940
TrulicityDulaglutide15$14,524
Repatha SureclickEvolocumab18$10,905
Metoprolol Succinate126$1,523
Ranolazine ErRanolazine17$1,424
Carvedilol126$1,108
ClopidogrelClopidogrel Bisulfate84$954
Atorvastatin Calcium102$814
Isosorbide Mononitrate ErIsosorbide Mononitrate44$673
Amiodarone Hcl18$522
Chlorthalidone31$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$115$78,96281 claims
NovartisEntresto$96$53,32346 claims
Novo NordiskOzempic$24$48,63139 claims
Johnson & JohnsonXarelto$121$36,81244 claims
PfizerEliquis$258$34,94037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →